The pavilion and precision medicine programs are supported by $40 million in philanthropic funding from Mort Harris in honor of his late wife Brigitte.
The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.
The company has reached agreements with investors for a direct offering of 2.2 million shares at $1 per share, for gross proceeds of about $2.2 million.
